SWOG clinical trial number
SWOG-9238 (INT-0134) (GOG-134) (NCCTG-92-61-51)
A Randomized Study of Intravenous Taxol at Three Dose Levels and G-CSF at Two Dose Levels in Platinum-Resistant Ovarian Carcinoma, Phase III (Intergroup)
Closed
Phase
Published
Abbreviated Title
A Randomized Study of Intravenous Taxol at Three Dose Levels and G-CSF at Two Dose Levels in Platinum-Resistant Ovarian Carcinoma, Phase III (Intergroup)
Activated
01/15/1993
Closed
02/06/1995
Research committees
Gynecologic Cancer
Publication Information Expand/Collapse
2003
Phase III trial of paclitaxel at two dose levels, the higher dose accompanied by filgrastim at two dose levels in platinum-pretreated epithelial ovarian cancer: an intergroup study
2001
Gender and other survival predictors in patients with metastatic melanoma on Southwest Oncology Group trials
1996
A randomized trial of paclitaxel (T) at 2 dose levels and filgrastim (G; G-CSF) at 2 doses in platinum (P) pretreated epithelial ovarian cancer (OVCA): A Gynecologic Oncology Group, SWOG, NCCTG and ECOG study.